

# Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial

Fedro A. Peccatori, MD, PhD<sup>1</sup> ; Samuel M. Niman, MS<sup>2,3</sup> ; Ann H. Partridge, MD, MPH<sup>4,5</sup> ; Monica Ruggeri<sup>6</sup> ; Marco Colleoni, MD<sup>7</sup> ; Cristina Saura, MD, PhD<sup>8,9</sup> ; Chikako Shimizu, MD<sup>10</sup> ; Anna B. Satersdal, MD<sup>11</sup>; Judith R. Kroep, MD<sup>12,13</sup> ; Karen Gelmon, MD<sup>14</sup> ; Frederic Amant, MD, PhD<sup>15,16,17</sup> ; Audrey Mailliez, MD<sup>18</sup> ; Halle C.F. Moore, MD<sup>19</sup> ; Manuel Ruiz-Borrego, MD<sup>20,21</sup> ; Janice M. Walshe, MD<sup>22,23,24</sup> ; Virginia F. Borges, MD<sup>25</sup> ; Andrea Gombos, MD, PhD<sup>26</sup> ; Akemi Kataoka, MD<sup>27</sup> ; Christine Rousset-Jablonski, MD, PhD<sup>28,29,30</sup> ; Simona Borstnar, MD, PhD<sup>31</sup>; Junko Takei, MD<sup>32</sup> ; Jeong E. Lee, MD, PhD<sup>33,34</sup> ; Christobel Saunders, MD<sup>35,36</sup> ; Vesna Bjelic-Radisic, MD, PhD<sup>37,38</sup>; Snezana Susnjar, MD<sup>39</sup> ; Fatima Cardoso, MD, PhD<sup>40</sup> ; Natalie J. Klar, MD<sup>41</sup> ; Teresa Ferreiro, PhD<sup>42</sup> ; Sarra El-Abed, MD, PhD<sup>43</sup> ; Martine Piccart, MD<sup>26,43</sup> ; Larissa A. Korde, MD, MPH<sup>44</sup>; Aron Goldhirsch, MD<sup>45,46</sup>; Richard D. Gelber, PhD<sup>2,3,5,47,48</sup> ; Olivia Pagani, MD<sup>49,50,51</sup>; and Hatem A. Azim Jr, MD, PhD<sup>52</sup> ; for the International Breast Cancer Study Group and the POSITIVE Trial Collaborators

DOI <https://doi.org/10.1200/JCO-24-02697>

## ABSTRACT

**PURPOSE** We investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth in the POSITIVE trial.

**PATIENTS AND METHODS** POSITIVE is a prospective trial that demonstrated no increased short-term risk of BC events in women with early HR+ BC who interrupted endocrine therapy (ET) to attempt pregnancy. We describe the frequency, duration, and laterality of breastfeeding and estimate the cumulative incidence of BC events by breastfeeding status.

**RESULTS** At a median follow-up of 41 months, 317 patients had at least one live birth and 313 were eligible for this analysis. A total of 196 of 313 (62.6%) patients breastfed. A total of 130 of the 167 women (77.8%) who had breast-conserving surgery breastfed, and 90 of 130 (69.2%) breastfed from the unaffected breast only. Sixty-six of the 146 women (45.2%) who underwent unilateral mastectomy breastfed. The frequency of breastfeeding was higher in women older than 35 years (67.6% v 55.7%) and in those without previous children (66.4% v 48.5%). Over half (103 of 196, 52.6%) of women breastfed their first live birth for >4 months (median 4.4 months; 95% CI, 4.0 to 5.3). The cumulative incidence of a BC event at 24 months from first on-study live birth was 3.6% and 3.1% in the breastfeeding and nonbreastfeeding groups, respectively (0.5% difference; 95% CI, –4.3% to 5.2%).

**CONCLUSION** In POSITIVE, two thirds of women who gave birth after BC diagnosis breastfed, mostly for 4 months or more. In early follow-up, we did not observe differences in BC-related events in women who breastfed compared with those who did not. These results are key for women who wish to pursue pregnancy and breastfeeding after BC.

## ACCOMPANYING CONTENT

 Appendix  
 Data Sharing Statement

Accepted May 23, 2025

Published July 9, 2025

J Clin Oncol 00:1-8

© 2025 by American Society of Clinical Oncology



[View Online Article](#)

## INTRODUCTION

With the rising trend of delaying childbearing, more women are diagnosed with breast cancer (BC) before starting or completing their families.<sup>1</sup> These women often inquire into the feasibility of future pregnancy and breastfeeding and whether either could have a detrimental impact on their disease outcomes.

Data on breastfeeding in women with a history of BC are limited to retrospective case series or surveys focused on the

feasibility of breastfeeding in this setting.<sup>2–5</sup> Most of the published papers are qualitative analysis on <100 patients<sup>6</sup> or focus on specific patient populations,<sup>7</sup> and thus, the full picture of breastfeeding after BC and its potential impact on prognosis have not been adequately evaluated yet.

Recently, we reported the results of the POSITIVE trial, a prospective single-arm trial evaluating the safety of temporary interruption of endocrine therapy (ET) to attempt pregnancy in young patients with BC.<sup>8</sup> At a median follow-up of 41 months, no higher short-term risk of BC events was

## CONTEXT

### Key Objectives

Is breastfeeding feasible and safe for patients with breast cancer (BC) interrupting endocrine treatment to seek pregnancy?

### Knowledge Generated

A total of 62.6% of included patients breastfed, and 52.6% of them breastfed for more than 4 months. Breastfeeding was more frequent in women who had breast-conserving surgery. In this group, breastfeeding was predominantly from the contralateral breast. The cumulative incidence of BC events at 24 months was 3.6% and 3.1% in the breastfeeding and nonbreastfeeding groups, respectively.

### Relevance (K.D. Miller)

Breastfeeding is beneficial for babies and mothers but exposes women to higher estrogen levels, raising concern that it may increase the risk of recurrence. The POSITIVE trial provides reassuring data on the safety of pregnancy and the ability to successfully breastfeed after pregnancy without an obvious increased risk.\*

\*Relevance section written by JCO Senior Deputy Editor Kathy D. Miller, MD.

found. Here, we report the results of one of the main secondary end points of the trial: breastfeeding patterns, behavior, and relation to BC outcomes.

## PATIENTS AND METHODS

POSITIVE is a prospective, international, multicenter, single-arm trial. Trial design, patient characteristics, and the primary end point analysis were previously published.<sup>8,9</sup> In brief, eligible patients had stage I to III BC, were 42 years or younger at enrollment, and received 18–30 months of ET before inclusion. The trial recruited 518 patients, in 116 centers, across 20 countries from December 2014 to December 2019.

The protocol specified a temporary interruption of ET for up to 2 years to allow for pregnancy, delivery, and breastfeeding, if desired and/or feasible. Data on breastfeeding were prospectively collected for the first pregnancy and included breastfeeding rate, laterality, and duration. All patients were strongly encouraged to resume ET after conclusion of pregnancy or breastfeeding (whichever was later) to complete 5–10 years as planned.

The study was conducted by the International Breast Cancer Study Group (IBCSG), which was responsible for trial design, data collection, management, and statistical analysis. Participating centers were affiliated with cooperative groups of the Breast International Group and the US National Clinical Trials Network.

The study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines, the Declaration of Helsinki, and local clinical research regulations. The protocol was approved by the institutional review board at all participating centers. All

patients provided written informed consent. Study progress was reviewed every 6 months by the IBCSG Data and Safety Monitoring Committee.

The evaluable data set consisted of women who had at least one live birth while on study. The breastfeeding pattern included duration for all patients and laterality in patients who underwent breast-conserving surgery (BCS).


The Kaplan–Meier method was used to estimate the duration of breastfeeding for the first live birth among those who initiated breastfeeding; all women who breastfed did so for at least the first live birth. If an offspring was still being breastfed at the time of the analysis, breastfeeding duration was censored at the most recent follow-up date.

The cumulative incidence of BC events (1 minus Kaplan–Meier) was estimated by breastfeeding status. For this analysis, using a landmark analysis approach, we redefined breast cancer–free interval (BCFI) from the time of first post-treatment live birth to the first invasive local, regional, or distant BC recurrence or the first instance of contralateral disease. Patients without a BCFI event were censored at the date last known to be alive and BC-free.

## RESULTS

### Patient Characteristics

At database lock, 497 women were evaluable for pregnancy, of whom 317 (63.8%) had at least one live birth (365 babies born; Fig 1). Of the 317 evaluable patients, four (1.2%) had bilateral mastectomy, two for bilateral disease and two for unilateral disease, and were removed from this analysis, leaving 313 eligible patients for breastfeeding analysis.



**FIG 1.** Trial enrollment and analysis population. BF, breastfed.

Among the 313 eligible patients, the median time from enrollment to first live birth was 18 months (IQR, 14–23). A total of 146 of 313 (46.6%) women had unilateral mastectomy, and 167 of 313 (53.4%) BCS. A total of 196 of 313 (62.6%) breastfed at least one child, including 163 who fed exactly one, 31 who fed two children, one who fed three, and one who fed four.

### Breastfeeding Behavior

Figure 2 illustrates the frequency of breastfeeding according to patient characteristics, and Appendix Table A1 (online only) shows the underlying percentages. Of the 196 patients who breastfed their first live child, 113 (57.7%) had previously received chemotherapy (mostly anthracycline- and taxane-based), 130 breastfed after BCS (66.3%), 90 of 130 (69.2%) breastfed from the contralateral breast only, 38 of 130 (29.2%) breastfed from both breasts, and two (1.5%) breastfed from the affected breast only. Of the 40 patients who breastfed from the affected breast, 34 (85.0%) had previously received radiation therapy.


The frequency of breastfeeding was higher not only in women who underwent BCS (77.8% v 45.2%) but also in those with no previous children (66.4% v 48.5%) and those at least 35 years old (67.6% v 55.7%). Women from Asia/Pacific/Middle East breastfed with higher frequency (85.7%), compared with those from Europe (62.7%) or North America (51.2%).

The median duration of breastfeeding for the first on-study live birth was 4.4 months (95% CI, 4.0 to 5.3), and the breastfeeding duration was at least 6 months, 1 year, or 2 years in 37.1%, 12.8%, and 1.5% of patients, respectively (Fig 3). Duration of previous ET and time from enrollment to first live birth were not associated with breastfeeding frequency or duration (Table 1 and Appendix Figs A1 and A2).

### Breast Cancer Outcomes After First Live Birth

After a median follow-up of 22 months (IQR, 13–34 months) from first live birth, we did not observe a higher cumulative incidence of BCFI events among patients who breastfed in comparison with those who did not (Fig 4). The 12-month estimates of BCFI after live birth were 1.1% (95% CI, 0.3% to 4.4%) and 1.9% (95% CI, 0.5% to 7.5%) in the breastfeeding and nonbreastfeeding cohorts, respectively. At 24 months, the estimates were 3.6% (95% CI, 1.5% to 8.5%) and 3.1% (95% CI, 1.0% to 9.5%), with an absolute difference of 0.4% (95% CI, –4.3% to 5.2%).

A total of nine BC events occurred after the first live birth, six of 196 in the breastfeeding cohort (two local, one contralateral, one regional, and two distant) and three of 117 in the nonbreastfeeding cohort (one local, one regional, and one distant).



**FIG 2.** Breastfeeding proportion according to patient characteristics. The dashed line indicates the overall percentage of patients who breastfed (62.6%).


## DISCUSSION

To our knowledge, this is the largest prospective study to evaluate breastfeeding frequency, patterns, and relation to BC outcomes in women previously diagnosed with BC, providing valuable information for comprehensive breastfeeding counseling.

With the limitations that the trial had a highly motivated patient and health care provider population, we found that

most women who gave birth in the POSITIVE study were able to breastfeed and that those who underwent BCS predominantly breastfed from the contralateral breast. After a median follow-up of 41 months from enrollment (22 months from first live birth), breastfeeding was not associated with a higher incidence of BCFI events.

There is a large body of evidence supporting the health advantages of breastfeeding, for both the mother and the newborn.<sup>10-12</sup> Breastfeeding frequency in the general



**FIG 3.** Breastfeeding duration (months) since initiation.

population is highly influenced by breastfeeding counseling and training, community support programs, adherence to the international code of marketing of breast milk substitutes, and maternity protection in the workplace. Globally, 46% of newborns are breastfed within an hour from birth, with striking differences among countries.<sup>13</sup> Women who had a previous diagnosis of BC face additional hurdles, mainly because of the scarce support and lack of counseling, the availability of only one healthy breast to breastfeed, and the prognostic unknowns of breastfeeding after BC.<sup>5,14,15</sup> In our analysis, 196 of 313 (62.6%) women who gave birth and did not have bilateral mastectomy breastfed, a lower percentage than that reported in the study by Sella et al. In their study, 143 young BC survivors who reported one or more live births were surveyed for breastfeeding habits. One hundred fifteen


responded, and 94 were included in the analysis cohort. Of these, 39 of 94 had bilateral mastectomy, and of the remaining 55 patients, 52 (95%) breastfed. They were mainly White and non-Hispanic and had high support from lactation consultants and access to online information.<sup>5</sup> In our study, we could not ascertain antenatal psychological and socioeconomic factors that are known to affect successful breastfeeding,<sup>16</sup> nor the exact reasons to start or not to start breastfeeding, but the correlation between higher breastfeeding frequency and age older than 35 years and BCS are consistent with those already reported by others.<sup>3,5</sup> Of note, also, the higher breastfeeding frequency in women from Asia/Pacific/Middle East compared with those from Europe or North America is in line with the reported breastfeeding frequency in the general population.<sup>13</sup> Unfortunately, in our study, granular information on the

**TABLE 1.** Duration of Previous ET and Time From Enrollment to First Live Birth (months) by Breastfeeding Status

| Breastfeeding Status                                                  | No. | Duration of Previous ET (months) |        |     | Time from Enrollment to First Live Birth (months) |        |     |
|-----------------------------------------------------------------------|-----|----------------------------------|--------|-----|---------------------------------------------------|--------|-----|
|                                                                       |     | P25                              | Median | P75 | P25                                               | Median | P75 |
| Patients who had a live birth and did not have a bilateral mastectomy | 313 | 20                               | 23     | 27  | 14                                                | 18     | 23  |
| Breastfed longer than 4 months <sup>a</sup>                           |     |                                  |        |     |                                                   |        |     |
| Yes                                                                   | 103 | 19                               | 23     | 28  | 14                                                | 16     | 20  |
| No                                                                    | 93  | 21                               | 24     | 27  | 14                                                | 18     | 23  |
| Did not breastfeed                                                    | 117 | 20                               | 23     | 26  | 14                                                | 18     | 24  |

Abbreviation: ET, endocrine therapy.

<sup>a</sup>Among first live births.



**FIG 4.** BCFI events among patients who breastfed and did not breastfeed after the first live birth. BCFI was censored at day 1 for 18 patients: because of no disease follow-up through live birth (six and eight for the breastfed and did not breastfeed cohorts, respectively) or because of having a BCFI event before the first live birth (1 and 3, respectively). BCFI, breast cancer–free interval.

barriers and facilitators of breastfeeding and the impact of breastfeeding on quality of life were not available and this should be considered as a limitation.

Among women who underwent BCS and breastfed, the majority (69.2%) breastfed from the unaffected breast only. Even if the reasons for choosing the unaffected breast were not investigated in our study, reduced milk production from the irradiated breast and pain and discomfort during latching could explain this behavior, as described in other studies.<sup>3,5</sup> The reasons for the lower breastfeeding rate among patients with previous mastectomy remain to be elucidated. It is plausible that the negative impact of mastectomy on woman's body image<sup>17</sup> might have potentially contributed to such observation, as might have the lack of appropriate counseling. In addition, women who placed less value on future breastfeeding might have been more likely to accept mastectomy. In the study by Sella et al, one woman who had unilateral mastectomy did not breastfeed because she believed that she would not have sufficient milk supply and two indicated that they were not interested in breastfeeding.<sup>5</sup>

The median duration of breastfeeding in our study was 4.4 months. As all women attempted pregnancy and breastfeeding before completing their 5–10 years of adjuvant ET and were strongly encouraged to resume treatment within a timeframe of 2 years, as per the POSITIVE trial protocol, it is likely that this had an impact

on the decision to breastfeed and/or its duration. Another potential limitation to the breastfeeding duration may be the difficulty in interpreting breast imaging (mammography and/or magnetic resonance imaging), even if it is feasible during breastfeeding. This needs to be considered in interpreting the results and underlines the importance of adequate counseling about breastfeeding in women who need to resume adjuvant ET.

As only 30 of 190 patients screened for *BRCA* had a pathogenic variant, we could not correlate *BRCA* status with breastfeeding, but data on breastfeeding after BC in carriers of *BRCA* 1 or 2 pathogenic variants have been recently presented and also confirmed the feasibility and safety of breastfeeding in this special population.<sup>7</sup>

Despite the relatively short follow-up from trial enrollment (median 41 months) and from subsequent first live birth (median 22 months), to our knowledge, this is the first large prospective study that addresses the question of the safety of breastfeeding after BC. We found that, irrespective of breastfeeding status, patients had excellent outcomes, with only nine BCFI events, including three local recurrences, equally distributed in the breastfeeding and nonbreastfeeding group. At 24 months since breastfeeding initiation, the percentage of BCFI events was 3.6% in the breastfeeding group and 3.1% in the nonbreastfeeding group, with an absolute difference of 0.5% and wide 95% confidence intervals (95% CI, –4.3% to 5.2%).



The few BC events observed in our study might in part be related to the relatively short follow-up time, as stated above. As hormone-responsive BC recurrences may occur up to 20 years after diagnosis,<sup>18</sup> the short follow-up remains a limitation of our study. The planned longer follow-up will clarify the long-term BC event patterns in patients who do and do not breastfeed after live birth.

## AFFILIATIONS

- <sup>1</sup>Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy
- <sup>2</sup>International Breast Cancer Study Group Statistical Center, Boston, MA
- <sup>3</sup>Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
- <sup>4</sup>Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
- <sup>5</sup>Harvard Medical School, Boston, MA
- <sup>6</sup>Program for Young Patients, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland
- <sup>7</sup>Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- <sup>8</sup>Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- <sup>9</sup>SOLTI Breast Cancer Research Group, Barcelona, Spain
- <sup>10</sup>Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan
- <sup>11</sup>Breast Cancer Unit, Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway
- <sup>12</sup>Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands
- <sup>13</sup>Dutch Breast Cancer Research Group (BOOG), Amsterdam, the Netherlands
- <sup>14</sup>BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC, Canada
- <sup>15</sup>Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium
- <sup>16</sup>Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium
- <sup>17</sup>Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, the Netherlands
- <sup>18</sup>Department of Medical Oncology, Breast Cancer Unit, Centre Oscar Lambret, Lille, France
- <sup>19</sup>Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
- <sup>20</sup>GEICAM Spanish Breast Cancer Group, Madrid, Spain
- <sup>21</sup>Hospital Virgen del Rocío Sevilla, Sevilla, Spain
- <sup>22</sup>Cancer Trials Ireland, Dublin, Ireland
- <sup>23</sup>Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland
- <sup>24</sup>Tallaght University Hospital, Dublin, Ireland
- <sup>25</sup>Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO
- <sup>26</sup>Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium
- <sup>27</sup>Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
- <sup>28</sup>Department of Surgery, Leon Berard Cancer Centre, Centre Léon Bérard, Lyon, France
- <sup>29</sup>Unité INSERM U1290 RESHAPE, Lyon, France
- <sup>30</sup>Service de Gynécologie-Obstétrique, Hôpital Femme Mère Enfant, Bron, France

In conclusion, our data provide prospective new evidence on the pattern of breastfeeding and its safety in women with a history of BC. Based on current data, breastfeeding is feasible and is not associated with a higher short-term rate of BC-related events. These results provide much needed information for young women worldwide who are considering pregnancy and breastfeeding after BC diagnosis.

- <sup>31</sup>Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia
- <sup>32</sup>St Luke's International Hospital, Breast Center, Tokyo, Japan
- <sup>33</sup>Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- <sup>34</sup>Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea
- <sup>35</sup>Department of Surgery, University of Melbourne, Melbourne, VIC, Australia
- <sup>36</sup>Royal Melbourne Hospital, Melbourne, VIC, Australia
- <sup>37</sup>Breast Unit, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany
- <sup>38</sup>Austrian Breast and Colorectal Study Group (ABCSG), Vienna, Austria
- <sup>39</sup>Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
- <sup>40</sup>Breast Unit, Champalimaud Foundation and Advanced Breast Cancer (ABC) Global Alliance, Lisbon, Portugal
- <sup>41</sup>New York University Langone's Perlmutter Cancer Center, Breast Cancer Center, New York, NY
- <sup>42</sup>Soul Reconnect, Barcelona, Spain
- <sup>43</sup>Breast International Group, Brussels, Belgium
- <sup>44</sup>Breast and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD
- <sup>45</sup>International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland
- <sup>46</sup>IEO, European Institute of Oncology, IRCCS, Milan, Italy
- <sup>47</sup>Frontier Science Foundation, Boston, MA
- <sup>48</sup>Harvard TH Chan School of Public Health, Boston, MA
- <sup>49</sup>Geneva University Hospitals, Geneva, Switzerland
- <sup>50</sup>Lugano University, Lugano, Switzerland
- <sup>51</sup>Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
- <sup>52</sup>Cairo Cure Oncology Center, Cairo, Egypt

## CORRESPONDING AUTHOR

Fedro A. Peccatori, PhD, MD; e-mail: fedro.peccatori@gmail.com.

## PRIOR PRESENTATION

Presented at ESMO Congress, Barcelona, Spain, September 13-17, 2024.

## SUPPORT

The POSITIVE trial was supported by the ETOP IBCSG Partners Foundation (globally) and the Alliance for Clinical Trials in Oncology (in North America), in collaboration with the Breast International Group (BIG), the BIG cooperative groups, and the National Clinical Trials Network of the National Cancer Institute. Globally, the trial received grant support for central or local trial conduct from the following: the International Breast Cancer Study Group (IBCSG); Frontier Science and Technology Research Foundation; Southern Europe (Frontier Southern Europe); Rising Tide Foundation for Clinical Cancer Research (CCR-15-120, CCR-20-200, CCR-24-150); Pink Ribbon Switzerland; Swiss Cancer League (KLS-3361-02); San Salvatore Foundation; Swiss Group for

Clinical Cancer Research; Clinical Cancer Research Foundation of Eastern Switzerland; Ms Elisabetta Pavesi, Roche Diagnostics International; Verein Bärig, Swiss Cancer Foundation; Ms Christine Hafner and Mr Marc Wyss, Piajoh Fondazione di Famiglia; Gruppo Giovani Pazienti “Anna dai Capelli Corti”; and Schweizer Frauenlauf Bern—all in Switzerland; BIG Against Breast Cancer and the Baillet Latour Fund, Belgium; Gateway for Cancer Research (G-15-1900) and Breast Cancer Research Foundation—both in the United States; Fondazione Umberto Veronesi, Italy; C & A, Germany; Dutch Cancer Society, the Netherlands; Norwegian Breast Cancer Society and Pink Ribbon—both in Norway; ELGC K.K. and Pink Ring—both in Japan; Mr Yong Seop Lee, Ms Sun Hee Kang, and Korean Breast Cancer Foundation—all in South Korea; and other private donors. In North America, the Alliance for Clinical Trials in Oncology receives support from the National Cancer Institute of the National Institutes of Health (NIH); Alliance for Clinical Trials in Oncology National Cancer Institute Community Oncology Research Program [NCORP] grant UG1CA189823 and the biorepository resource grant U24CA196171; the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network (ECOG-ACRIN) receives support under grant UG1CA189828; SWOG Cancer Research Network receives support under NIH grants UG1CA189974 and U10CA180888; and NRG Oncology receives support under NIH grant U10CA180868 and NCORP grant UG1CA189867. Canadian Cancer Trials Group (CCTG) participation in the trial was supported through its grant from the National Cancer Institute of the NIH (CA180863). Funding support was received from the Dutch Cancer Society, the Netherlands (KaWeFis Batch7/7723). Additional programmatic funding support for the CCTG was provided by the Canadian Cancer Society (707213) and the Canada Foundation for Innovation. In addition, the trial received support from RETHINK Breast Cancer, Canada, and the Gilson Family Foundation, United States.

## CLINICAL TRIAL INFORMATION

NCT02308085 (POSITIVE)

## AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO-24-02697>.

## REFERENCES

1. Peccatori FA, Azim HA Jr, Orecchia R, et al: Cancer, pregnancy and fertility: ESMO clinical Practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 24:v160-v170, 2013 (suppl 6)
2. Gorman JR, Usita PM, Madlensky L, et al: A qualitative investigation of breast cancer survivors’ experiences with breastfeeding. *J Cancer Surviv* 3:181-191, 2009
3. Azim HA Jr, Belletini G, Liptrott SJ, et al: Breastfeeding in breast cancer survivors: Pattern, behaviour and effect on breast cancer outcome. *Breast* 19:527-531, 2010
4. Bhurosy T, Niu Z, Heckman CJ: Breastfeeding is possible: A systematic review on the feasibility and challenges of breastfeeding among breast cancer survivors of reproductive age. *Ann Surg Oncol* 28:3723-3735, 2021
5. Sella T, Sorouri K, Rosenberg SM, et al: Breastfeeding experiences among young breast cancer survivors: A survey study. *Cancer* 131:e35585, 2025
6. Peccatori FA, Prosperi Porta R, Azim HA Jr: Reproductive autonomy and breastfeeding in young breast cancer survivors. *Cancer* 131:e35602, 2025
7. Blondeaux E, Delucchi V, Mariamidze E, et al: Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study. ESMO Congress, 2024. Abstract 18150, 2024
8. Partridge AH, Niman SM, Ruggeri M, et al: Interrupting endocrine therapy to attempt pregnancy after breast cancer. *N Engl J Med* 388:1645-1656, 2023
9. Partridge AH, Niman SM, Ruggeri M, et al: Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. *Breast* 59:327-338, 2021
10. Yang S, Martin RM, Oken E, et al: Breastfeeding during infancy and neurocognitive function in adolescence: 16-year follow-up of the PROBIT cluster-randomized trial. *PLOS Med* 15:e1002554, 2018
11. Krol KM, Kamboj SK, Curran HV, et al: Breastfeeding experience differentially impacts recognition of happiness and anger in mothers. *Sci Rep* 4:7006, 2014
12. Speyer LG, Hall HA, Ushakova A, et al: Longitudinal effects of breast feeding on parent-reported child behaviour. *Arch Dis Child* 106:355-360, 2021
13. UNICEF WHO: Global Breastfeeding COLLECTIVE-Global breastfeeding scorecard. 2023. <https://www.unicef.org/documents/global-breastfeeding-scorecard-2023>
14. Linkeviciute A, Notarangelo M, Buonomo B, et al: Breastfeeding after breast cancer: Feasibility, safety, and ethical perspectives. *J Hum Lact* 36:40-43, 2020
15. Smorti M, Ponti L, Cassani C, et al: From pregnancy to lactation: When the pathway is complicated by cancer. *J Hum Lact* 39:478-487, 2023
16. Amiel Castro R, Glover V, Ehler U, et al: Antenatal psychological and socioeconomic predictors of breastfeeding in a large community sample. *Early Hum Dev* 110:50-56, 2017
17. Türk KE, Yılmaz M: The effect on quality of life and body image of mastectomy among breast cancer survivors. *Eur J Breast Health* 14:205-210, 2018
18. Pan H, Gray R, Braybrooke J, et al: 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med* 377:1836-1846, 2017

## DATA SHARING STATEMENT

A data sharing statement provided by the authors is available with this article at DOI <https://doi.org/10.1200/JCO-24-02697>.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Fedro A. Peccatori, Ann H. Partridge, Monica Ruggeri, Cristina Saura, Karen Gelmon, Christobel Saunders, Natalie J. Klar, Teresa Ferreiro, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani, Hatem A. Azim Jr  
**Financial support:** Ann H. Partridge, Judith R. Kroep, Aron Goldhirsch  
**Administrative support:** Ann H. Partridge, Monica Ruggeri  
**Provision of study materials or patients:** Ann H. Partridge, Cristina Saura, Anna B. Satersdal, Judith R. Kroep, Frederic Amant, Manuel Ruiz-Borrego, Janice M. Walshe, Virginia F. Borges, Andrea Gombos, Junko Takei, Jeong E. Lee, Fatima Cardoso, Larissa A. Korde, Hatem A. Azim Jr  
**Collection and assembly of data:** Fedro A. Peccatori, Ann H. Partridge, Monica Ruggeri, Marco Colleoni, Chikako Shimizu, Anna B. Satersdal, Judith R. Kroep, Karen Gelmon, Frederic Amant, Janice M. Walshe, Virginia F. Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E. Lee, Christobel Saunders, Vesna Bjelic-Radicic, Snezana Susnjar, Fatima Cardoso, Larissa A. Korde  
**Data analysis and interpretation:** Fedro A. Peccatori, Samuel M. Niman, Ann H. Partridge, Chikako Shimizu, Karen Gelmon, Frederic Amant, Audrey Mailliez, Halle C.F. Moore, Manuel Ruiz-Borrego, Janice M. Walshe, Christobel Saunders, Vesna Bjelic-Radicic, Snezana Susnjar, Fatima Cardoso, Sarra El-Abed, Martine Piccart, Richard D. Gelber, Olivia Pagani, Hatem A. Azim Jr  
**Manuscript writing:** All authors  
**Final approval of manuscript:** All authors  
**Accountable for all aspects of the work:** All authors

## ACKNOWLEDGMENT

We sincerely thank the patients and their families, the study partners and supporters (IBCSG, BIG, all collaborative groups, NCI, all national funding bodies, charities, and private donors), the collaborators, and the current and former members of the trial’s committees and the investigators. Coauthor Aron Goldhirsch, MD, died on February 26, 2020.



## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

## Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/authors/author-center](http://ascopubs.org/jco/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://Open Payments)).

**Ann H. Partridge**

**Patents, Royalties, Other Intellectual Property:** Wolters Kluwer-royalties for authorship of UpToDate

**Open Payments Link:** <https://openpaymentsdata.cms.gov/physician/835197>

**Cristina Saura**

**Honoraria:** AstraZeneca, Daiichi Sankyo/AstraZeneca, Eisai Europe, Ltd, Zymeworks, Puma Biotechnology, Roche Pharma AG, Seagen, Solti, Phillips Health Works, Pfizer, Pierre Fabre, Exeter Pharmaceuticals

**Consulting or Advisory Role:** AstraZeneca, Daiichi Sankyo, Eisai, MediTech, Novartis, Pfizer, Philips Healthcare, Pierre Fabre, Puma Biotechnology, Seagen, Gilead Sciences, Pint Pharma, Synthon, Zymeworks, PharmaLex, Lilly, Menarini, F. Hoffmann LaRoche

**Speakers' Bureau:** AstraZeneca, Daiichi Sankyo/AstraZeneca, Pfizer, Pierre Fabre, Puma Biotechnology, Seagen, Exeter Pharmaceuticals, Lilly

**Research Funding:** Puma Biotechnology (Inst), Roche (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Bristol Myers Squibb (BMS) (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Roche (Inst), Genentech (Inst), GlaxoSmithKline (Inst), InnoUp (Inst), Lilly (Inst), MacroGenics (Inst), Menarini (Inst), Merus (Inst), Novartis (Inst), Pfizer (Inst), Sanofi/Aventis (Inst), Seagen (Inst), AstraZeneca (Inst), Amgen (Inst), BeiGene (Inst), Debiopharm Group (Inst), Janssen-Cilag SA (Inst), Merck Health KGAA, Merck Sharp & Dohme (Inst), Mirati Therapeutics (Inst), PharmaMar (Inst), SERVIER (Inst), Taiho Pharma USA Inc (Inst), Spanish Association Against Cancer Scientific Foundation and Cancer Research UK (Inst)

**Expert Testimony:** AX's consulting SARL, Boehringer Ingelheim, Bristol Myers Squibb/Sanofi, Genentech, InnoUp, Merck Sharp and Dohme Spain, Novartis, Sanofi

**Travel, Accommodations, Expenses:** Pfizer, Novartis, Roche, AstraZeneca, Puma Biotechnology, Daiichi Sankyo, Eisai Europe, Gilead Sciences, Lilly, Pierre Fabre, Seagen

**Chikako Shimizu**

**Honoraria:** AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Pfizer, Daiichi Sankyo/UCB Japan, Lilly Japan

**Consulting or Advisory Role:** Daiichi Sankyo/UCB Japan, Canon Medical System

**Research Funding:** Lilly

**Uncompensated Relationships:** AYA Oncology Alliance, Japanese Breast Cancer Society, Japanese Society of Medical Oncology

**Judith R. Kroep**

**Consulting or Advisory Role:** AstraZeneca (Inst), Novartis (Inst), Lilly (Inst), GlaxoSmithKline (Inst), Immagene (Inst), MSD (Inst), Daiichi Sankyo Europe GmbH (Inst)

**Research Funding:** AstraZeneca (Inst), Novartis (Inst), Philips Research (Inst)

**Travel, Accommodations, Expenses:** Daiichi Sankyo Europe GmbH (Inst)

**Karen Gelmon**

**Honoraria:** AstraZeneca, Merck Sharp & Dohme, Pfizer, Lilly, Gilead Sciences

**Consulting or Advisory Role:** Pfizer, AstraZeneca, Merck, Lilly, Gilead Sciences

**Research Funding:** Pfizer (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst)

**Frederic Amant**

**Honoraria:** Roche

**Consulting or Advisory Role:** MiMark

**Audrey Mailliez**

**Consulting or Advisory Role:** SEAGEN

**Travel, Accommodations, Expenses:** Lilly, Menarini, MSD Oncology, Novartis

**Halle C.F. Moore**

**Research Funding:** Daiichi Sankyo (Inst), Roche (Inst), AstraZeneca (Inst), Sermonix Pharmaceuticals (Inst), Seagen (Inst), Pfizer (Inst)

**Manuel Ruiz-Borrego**

**Honoraria:** Roche/Genentech, Pfizer, Novartis

**Consulting or Advisory Role:** Roche, Puma Biotechnology

**Janice M. Walshe**

**Honoraria:** Novartis, Daiichi Sankyo, Roche

**Travel, Accommodations, Expenses:** Novartis

**Virginia F. Borges**

**Consulting or Advisory Role:** Seagen, AstraZeneca, Gilead Sciences, Olema Oncology

**Research Funding:** Seagen (Inst), Olema Oncology (Inst), AstraZeneca (Inst)

**Travel, Accommodations, Expenses:** Olema Oncology

**Andrea Gombos**

**Honoraria:** Daiichi Sankyo (Inst), MSD Oncology (Inst), Roche (Inst), Novartis (Inst)

**Consulting or Advisory Role:** Daiichi Sankyo Belgium (Inst), AstraZeneca Belgium (Inst)

**Travel, Accommodations, Expenses:** Gilead Sciences (Inst), Daiichi Sankyo Belgium (Inst), Gilead Sciences (Inst), Lilly (Inst)

**Christine Rousset-Jablonski**

**Consulting or Advisory Role:** Gédéon Richter (Inst), Bayer (Inst), Astellas Pharma (Inst)

**Speakers' Bureau:** Bristol Myers Squibb (Inst), Merck (Inst), Novartis (Inst), Theramex (Inst)

**Research Funding:** Gédéon Richter (Inst), Bayer (Inst), Astellas Pharma (Inst)

**Travel, Accommodations, Expenses:** Gédéon Richter

**Simona Borstnar**

**Honoraria:** AstraZeneca, Lilly, Pfizer, Novartis, Roche, MSD Oncology, Sandoz, Gilead Sciences

**Consulting or Advisory Role:** Novartis, AstraZeneca, Roche, Pfizer, MSD Oncology, Lilly

**Junko Takei**

**Speakers' Bureau:** AstraZeneca

**Vesna Bjelic-Radisic**

**Speakers' Bureau:** Lilly (Inst), Pfizer (Inst), Mammutome (Inst), Roche (Inst)

**Travel, Accommodations, Expenses:** Pfizer

**Snezana Susnjar**

**Consulting or Advisory Role:** Lilly, Roche, Novartis

**Speakers' Bureau:** Pfizer, Lilly

**Research Funding:** Roche (Inst)

**Fatima Cardoso**

**Consulting or Advisory Role:** Roche, Novartis, Pfizer, AstraZeneca, Teva, Astellas Pharma, Merus, Celgene, Eisai, Daiichi Sankyo, Genentech, Merck Sharp & Dohme, Sanofi, Pierre Fabre, MacroGenics, Amgen, GE Healthcare, GlaxoSmithKline, Mylan, Mundipharma, Samsung Bioepis,

Medscape, Prime Oncology, IQvia, Gilead Sciences, Seagen, touchIME, Bayer

**Travel, Accommodations, Expenses:** Pfizer, Roche, AstraZeneca, Novartis

**Natalie J. Klar**

**Research Funding:** Merck (Inst)

**Sarra El-Abed**

**Employment:** argenx (I), Breast International Group

**Research Funding:** Novartis (Inst), Roche/Genentech (Inst), Pfizer (Inst), AstraZeneca (Inst), GlaxoSmithKline (Inst), Sanofi (Inst)

**Martine Piccart**

**Consulting or Advisory Role:** AstraZeneca, Lilly, MSD, Novartis, Pfizer, Menarini, Seagen, Roche/Genentech, NBE Therapeutics, Frame Therapeutics, Gilead Sciences

**Research Funding:** AstraZeneca (Inst), Lilly (Inst), MSD (Inst), Novartis (Inst), Pfizer (Inst), Roche/Genentech (Inst), Radius Health (Inst), Synthon (Inst), Servier (Inst), Immunomedics/Gilead (Inst), Menarini (Inst)

**Other Relationship:** Oncolytics

**Richard D. Gelber**

**Research Funding:** AstraZeneca (Inst), Roche (Inst), Merck (Inst)

**Olivia Pagani**

**Consulting or Advisory Role:** Debiopharm Group

**Hatem A. Azim Jr**

**Stock and Other Ownership Interests:** Innate Pharma

**Honoraria:** AstraZeneca, Roche

**Consulting or Advisory Role:** Diaccurate, Pep-Therapy, EnnoDC


**Travel, Accommodations, Expenses:** Novartis

No other potential conflicts of interest were reported.

## APPENDIX



**FIG A1.** Distribution of duration of previous ET (months) by breastfeeding longer than 4 months. ET, endocrine therapy.



**FIG A2.** Time from enrollment to first live birth (months) by breastfeeding longer than 4 months.

**TABLE A1. Patient Characteristics According to Breastfeeding Status**

| Characteristic                                                        | Total | Breastfed  | Did Not Breastfeed |
|-----------------------------------------------------------------------|-------|------------|--------------------|
|                                                                       | No.   | No. (%)    | No. (%)            |
| Patients who had a live birth and did not have a bilateral mastectomy | 313   | 196 (62.6) | 117 (37.4)         |
| Age at enrollment, years                                              |       |            |                    |
| <35                                                                   | 131   | 73 (55.7)  | 58 (44.3)          |
| ≥35                                                                   | 182   | 123 (67.6) | 59 (32.4)          |
| Previous birth                                                        |       |            |                    |
| Yes                                                                   | 66    | 32 (48.5)  | 34 (51.5)          |
| No                                                                    | 247   | 164 (66.4) | 83 (33.6)          |
| BMI                                                                   |       |            |                    |
| <25                                                                   | 216   | 143 (66.2) | 73 (33.8)          |
| 25 to <30                                                             | 57    | 34 (59.6)  | 23 (40.4)          |
| ≥30                                                                   | 37    | 17 (45.9)  | 20 (54.1)          |
| Unknown                                                               | 3     | 2 (66.7)   | 1 (33.3)           |
| Tumor size (cm)                                                       |       |            |                    |
| ≤2                                                                    | 206   | 138 (67.0) | 68 (33.0)          |
| >2                                                                    | 106   | 57 (53.8)  | 49 (46.2)          |
| Unknown                                                               | 1     | 1 (100.0)  | —                  |
| Nodal status                                                          |       |            |                    |
| pN0                                                                   | 201   | 133 (66.2) | 68 (33.8)          |
| pN+                                                                   | 112   | 63 (56.3)  | 49 (43.8)          |
| Breast surgery                                                        |       |            |                    |
| Breast-conserving procedure                                           | 167   | 130 (77.8) | 37 (22.2)          |
| Mastectomy                                                            | 146   | 66 (45.2)  | 80 (54.8)          |
| Previous chemotherapy                                                 |       |            |                    |
| Yes                                                                   | 197   | 113 (57.4) | 84 (42.6)          |
| No                                                                    | 116   | 83 (71.6)  | 33 (28.4)          |
| Adjuvant endocrine therapy                                            |       |            |                    |
| SERM only                                                             | 124   | 81 (65.3)  | 43 (34.7)          |
| SERM + OFS                                                            | 114   | 77 (67.5)  | 37 (32.5)          |
| AI + OFS                                                              | 50    | 24 (48.0)  | 26 (52.0)          |
| Other                                                                 | 25    | 14 (56.0)  | 11 (44.0)          |
| Continent                                                             |       |            |                    |
| Europe                                                                | 185   | 116 (62.7) | 69 (37.3)          |
| North America                                                         | 86    | 44 (51.2)  | 42 (48.8)          |
| Asia/Pacific/Middle East                                              | 42    | 36 (85.7)  | 6 (14.3)           |

Abbreviations: AI, aromatase inhibitors; OFS, ovarian function suppression; SERM, selective estrogen receptor modulator.